Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that its blockbuster anti-PD-1 drug Keytruda (pembrolizumab) has entered a Phase Ia/b trial in combination with South Korea-based PharmAbcine’s (KOSDAQ: 208340) VISTA-inhibiting biologic PMC-309 for the treatment of advanced or metastatic solid tumors. The study aims to determine the recommended dose, safety, and tolerability of the combination therapy as well as the standalone use of PMC-309.
PharmAbcine’s monoclonal antibody (mAb) targets VISTA in immunosuppressive cells, offering a differentiated mechanism of action that triggers an anti-cancer response by activating T-cells and monocytes and promoting the proliferation of M1 macrophages.- Flcube.com– Flcube.com
